What is Illumigyn?
Founded in 2012 in Israel, Illumigyn operates at the intersection of medical device innovation and digital health. The company has developed a sophisticated remote gynecological platform and specialized hardware designed to digitally document pap smear exams. By digitizing these critical procedures, Illumigyn enables healthcare providers to perform high-resolution examinations with greater precision and accessibility. This platform addresses long-standing inefficiencies in women's health diagnostics, providing a scalable solution that bridges the gap between clinical expertise and patient care in remote or underserved settings. The company's market position is defined by its commitment to improving diagnostic accuracy and patient outcomes through integrated, cloud-based medical imaging.
How much funding has Illumigyn raised?
Illumigyn has raised a total of $35M across 2 funding rounds:
Private Equity
$2M
Other Financing Round
$33M
Private Equity (2016): $2M, investors not publicly disclosed
Other Financing Round (2021): $33M led by Yozma Group
Key Investors in Illumigyn
Yozma Group
A pioneering venture capital firm that established the Israeli private equity market in 1993, specializing in direct investments and strategic business development for technology-driven companies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Illumigyn?
With the recent infusion of capital, Illumigyn is poised to scale its operations and expand its footprint in the global health tech market. The strategic focus will likely center on enhancing its digital platform capabilities, pursuing regulatory milestones in new territories, and deepening its integration with existing hospital information systems. As the company transitions into this next phase of maturity, the emphasis will shift toward commercialization and the widespread adoption of its remote diagnostic tools. By maintaining its focus on high-quality medical imaging and data-driven insights, Illumigyn is set to redefine the standard of care for gynecological screenings, potentially attracting further interest from institutional investors and strategic partners within the broader life sciences and medical technology ecosystem.
See full Illumigyn company page
